

Table 1: overview of study procedures

	Screening	Enrolment	Medical oncologist: intake	Diagnostic laparoscopy	Cycle #1	Cycles #2-4	One week after cycle #4	Cycles #5-8	One week after cycle #8	Cycles #9-12	One week after cycle #12	Last study visit
Multidisciplinary tumor board	X						X		X		X	
Medical history	X	X	X									
Inclusion and exclusion criteria	X	X	X									
Provide study information	X	X	X									
Written informed consent		X										
Physical examination		X	X		X	X		X		X		
Pre-operative screening		X										
Blood test: DPD and UGT1A1 genotype		X										
Blood test: organ functions		X			X	X		X		X		
Blood test: tumor marker <sup>a</sup>		X			X	X		X		X		
Blood test: pregnancy <sup>b</sup>		X										
Electrocardiogram		X										
Placement of port-a-cath				X								
Placement of peritoneal access port				X								
Thoracoabdominal CT scan <sup>c</sup>		X					X		X		X	
Systemic chemotherapy					X	X		X		X		
Intraperitoneal chemotherapy					X	X		X		X		
Clinical evaluation		X	X		X	X		X		X		X
Toxicity evaluation (CTCAE)					X	X		X		X		X
Patient Reported Outcomes Questionnaires		X			X		X		X		X	
Costs Questionnaires		X			X		X		X		X	
Pharmacokinetics					X							
Progression Free Survival							X		X		X	X
Overall Survival					X	X		X		X		X
Remove peritoneal access port <sup>d</sup>												X
Translational Research: blood		X					X		X		X	
Translational Research: ascites				X	X	X						

<sup>a</sup>Carcino-embryonic antigen; <sup>b</sup>Only determined in women of fertile age (<55 years); <sup>c</sup>Unless already performed <6 weeks before diagnostic laparoscopy; <sup>d</sup>On patient's request; CT, Computed Tomography; CTCAE, Common Terminology Criteria for Adverse Events; Marked in grey: study-specific procedures;